249 related articles for article (PubMed ID: 33519217)
21. Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature Review.
Ben-Zacharia AB; Walker B; Ross AP; Tornatore C; Edwards NC; Lipman Y; Phillips AL
Int J MS Care; 2023; 25(5):188-195. PubMed ID: 37720259
[TBL] [Abstract][Full Text] [Related]
22. The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis.
Hersh CM; Brook RA; Beren IA; Rohrbacker NJ; Lebson L; Henke C; Phillips AL
J Med Econ; 2021; 24(1):479-486. PubMed ID: 33739915
[TBL] [Abstract][Full Text] [Related]
23. Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab.
Geiger CK; Sheinson D; To TM; Jones D; Bonine NG
Neurol Ther; 2023 Oct; 12(5):1709-1728. PubMed ID: 37458897
[TBL] [Abstract][Full Text] [Related]
24. Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis.
Li P; Ladage VP; Berger J; Chahin S; Jhaveri M; Geremakis C; Doshi JA
Value Health; 2020 Mar; 23(3):328-334. PubMed ID: 32197728
[TBL] [Abstract][Full Text] [Related]
25. Impact of Switching to Fingolimod Versus Injectable Disease-Modifying Therapy Cycling on Risk of Multiple Sclerosis-Related Relapses: A Retrospective Analysis.
Vieira MC; Li Y; Meng X; Zhou H; Piao OW; Kutz C; Conway D
Int J MS Care; 2021; 23(2):73-78. PubMed ID: 33880083
[TBL] [Abstract][Full Text] [Related]
26. Treatment Patterns, Healthcare Resource Utilization, and Costs Among Medicare Patients with Multiple Sclerosis in Relation to Disease-Modifying Therapy and Corticosteroid Treatment.
Sanchirico M; Caldwell-Tarr A; Mudumby P; Hashemi L; Dufour R
Neurol Ther; 2019 Jun; 8(1):121-133. PubMed ID: 30565050
[TBL] [Abstract][Full Text] [Related]
27. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.
Burkhard A; Toliver J; Rascati K
J Manag Care Spec Pharm; 2021 Jul; 27(7):915-923. PubMed ID: 34185555
[No Abstract] [Full Text] [Related]
28. Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic.
Coyle PK; Gorritz M; Wade RL; Zhou Z; Khalid S; Maiese EM; Deshpande C; Shao QS
Mult Scler Relat Disord; 2023 Oct; 78():104881. PubMed ID: 37556938
[TBL] [Abstract][Full Text] [Related]
29. Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis.
Fox RJ; Mehta R; Pham T; Park J; Wilson K; Bonafede M
BMC Neurol; 2022 Jun; 22(1):211. PubMed ID: 35672686
[TBL] [Abstract][Full Text] [Related]
30. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS.
Vermersch P; Oh J; Cascione M; Oreja-Guevara C; Gobbi C; Travis LH; Myhr KM; Coyle PK
Mult Scler Relat Disord; 2020 Aug; 43():102158. PubMed ID: 32470857
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data.
Nicholas J; Boster A; Wu N; Yeh WS; Fay M; Kendter J; Huang MY; Lee A
Pharmacoecon Open; 2018 Mar; 2(1):31-41. PubMed ID: 29464673
[TBL] [Abstract][Full Text] [Related]
32. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
Lenz F; Harms L
Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
[TBL] [Abstract][Full Text] [Related]
33. Indirect impact of the COVID-19 pandemic on the care and outcomes of people with MS: A combined survey and insurance claims study.
Meltzer E; Charron O; Wozny J; Onuorah H; Montague A; Kline AC; Largent A; Krause TM; Freeman L
Mult Scler Relat Disord; 2023 Dec; 80():105085. PubMed ID: 37931487
[TBL] [Abstract][Full Text] [Related]
34. Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity.
Raimundo K; Tian H; Zhou H; Zhang X; Kahler KH; Agashivala N; Kim E
BMC Health Serv Res; 2013 Apr; 13():131. PubMed ID: 23565628
[TBL] [Abstract][Full Text] [Related]
35. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH
Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489
[TBL] [Abstract][Full Text] [Related]
36. Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies.
Alvarez E; Nair KV; Tan H; Rathi K; Gabler NB; Maiese EM; Deshpande C; Shao Q
J Med Econ; 2023; 26(1):494-502. PubMed ID: 36970763
[TBL] [Abstract][Full Text] [Related]
37. Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020.
Henderson M; Horton DB; Bhise V; Pal G; Bushnell G; Dave CV
JAMA Neurol; 2023 Aug; 80(8):860-867. PubMed ID: 37428482
[TBL] [Abstract][Full Text] [Related]
38. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
Vermersch P; Suchet L; Colamarino R; Laurendeau C; Detournay B
Mult Scler Relat Disord; 2020 Nov; 46():102521. PubMed ID: 32977077
[TBL] [Abstract][Full Text] [Related]
39. Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis.
Bonafede M; Mehta R; Kim G; Sruti I; Tian M; Pelletier C; Goldfarb N
Pharmacoecon Open; 2021 Mar; 5(1):23-34. PubMed ID: 33051856
[TBL] [Abstract][Full Text] [Related]
40. A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy.
Kozlicki MZ; Markley B; Shah NB; DeClercq J; Choi L; Zuckerman AD
Mult Scler Relat Disord; 2022 Jul; 63():103860. PubMed ID: 35609353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
